Edited by Peter Hillerberg2 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Japan's machine tool orders delivered the sharpest annual rise this cycle in August 2026. According to the Japan Machine Tool Builders' Association, total orders reached JPY 197,867m, up 64.7% on August 2025. Foreign orders were almost equally strong, rising 64.8% year-on-year to JPY 380,511m, with gains recorded across all tracked regions. That breadth matters: a single large buyer can flatter a monthly print, but demand spread across regions points to a wider capital-goods cycle rather than a one-off shipment. The series has not seen an annual increase of this size at any point in the current cycle.
Norway's zero-emission car registrations reached 18,456 vehicles in September 2026, the largest September on record since the European car totals series began in 2016. The previous September best was 13,949, set in 2021. The strength in battery-electric demand contrasts with a 17% year-on-year decline in plug-in hybrid registrations across the same European national totals dataset for September, suggesting buyer preference is shifting decisively toward full-electric. Singapore added its own data point: new battery-electric car registrations hit a record August in the Singapore cars dataset, while visitor arrivals from Malaysia reached 94,204 in August 2026, the largest August figure in six years, topping the prior best of 88,675 from August 2025.
Medicare Advantage penetration reached 51.14% in June 2026, the highest reading since the Medicare series began in 2013, with 36.1 million beneficiaries enrolled. On the credit side, captive finance gross receivables reached USD 279.6bn in Q2 2026, the largest second quarter on record since 2012, fractionally ahead of the USD 279.4bn logged in Q2 2025. The same captive finance dataset also recorded the largest Q2 for recoveries since 2023, a detail worth watching alongside the headline receivables number.
The ORTEX nuclear output dataset shows SO reactor output running 10.0 standard deviations below its own history as of 9 September 2026. For ABBV, the drug trials dataset records trial completion date slippage at 2.1 standard deviations below its own history as of 22 September, meaning trial timelines are running ahead of schedule relative to the series norm. LKFN sees Wikipedia views 10.0 standard deviations above its own history as of 27 September, according to the retail attention dataset, an unusual spike in public interest for a regional bank.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
